<DOC>
	<DOCNO>NCT00794898</DOCNO>
	<brief_summary>This open-label program Remicade treatment patient active rheumatoid arthritis ( RA ) despite treatment methotrexate ( MTX ) determine onset efficacy infliximab .</brief_summary>
	<brief_title>Efficacy Remicade Treatment Active Rheumatoid Arthritis Despite Methotrexate ( Study P03027 )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Men woman , &gt; =18 &lt; =75 year age . Diagnosis RA accord revised 1987 criterion American Rheumatism Association ( Arnett et al. , 1988 ) . The disease diagnose least 6 month prior Screening . Patients active disease , opinion physician , despite concomitant use DMARDS . Evidence active disease may include follow : 6 swollen tender joint ; 2 follow Morning stiffness &gt; 45 minute Creactive protein &gt; 2.0 mg/L ESR &gt; 28 mm/h Patients must use oral parenteral MTX least 2 month break ( ) treatment 2 week total period . Patients must stable dose &gt; =7.5 mg/wk ( IM , SQ , PO ) least 8 week prior Screening . Men woman childbearing potential must use adequate birth control measure ( abstinence , oral contraceptive , IUD , barrier method spermicide , surgical sterilization ) continue precaution 6 month receive last infusion . Patients must stable dose folic acid prophylaxis least 4 week prior Screening . Patients use oral corticosteroid NSAIDs , must stable dose least 4 week prior Screening , must continue treatment period . If currently use corticosteroid NSAIDs , patient must receive corticosteroid NASIDs least 4 week prior Screening . Patients must able adhere program visit schedule protocol requirement . Patients must capable give informed consent consent must obtain prior screen procedure . Pregnant woman , nurse mother plan pregnancy within 1.5 year enrollment Patients incapacitate , largely wholly bedridden confine wheelchair , little ability selfcare . Patients current systemic inflammatory condition sign symptom might confound evaluation benefit Remicade therapy , eg , Lyme disease , rheumatic disease RA . Use DMARDS MTX within 4 week prior Screening . Use intraarticular , IM , IV . corticosteroid ( include IM ACTH ) within 4 week prior Screening . Prior administration therapeutic agent target reduce TNF ( eg , Etanercept , pentoxifylline , thalidomide antiCD4+ antibody ) within previous 6 month . Treatment investigational drug within previous 6 month . A history know allergy murine protein . Serious infection , hepatitis , pneumonia , pyelonephritis previous 3 month . Less serious infection previous 3 month , acute upper respiratory tract infection ( cold ) uncomplicated urinary tract infection need consider exclusion discretion treat physician . History opportunistic infection herpes zoster within 2 month Screening . Evidence active CMV , active pneumocystis carinii , drug resistant atypical mycobacterium , etc . Documented HIV infection . Current sign symptom severe , progressive uncontrolled renal , hepatic , hematologic , endocrine , pulmonary , cardiac , neurologic cerebral disease . Any currently know malignancy premalignant lesion history malignancy within past 5 year . Patients alcoholism , alcoholic liver disease , chronic liver disease . Patients positive PPD within 3 month chest XRay suggestive active TB previous exposure TB . Patients CHF , even asymptomatic require medication must exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>